Annual report
4078.TEDINET S100Q016
Period2020-04-01 → 2021-03-31
Filed2023-01-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100LJGA.
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥84.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥87.2bn | 2019-04-01 → 2020-03-31 | Cons. | Net sales |
| Revenue | ¥89.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥87.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥83.9bn | 2016-04-01 → 2017-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.3bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Operating income | ¥4.0bn | 2019-04-01 → 2020-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.0bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.2bn | 2019-04-01 → 2020-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2016-04-01 → 2017-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.0bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.0bn | 2019-04-01 → 2020-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.8bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2019-04-01 → 2020-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2016-04-01 → 2017-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥2.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Net income | ¥2.7bn | 2019-04-01 → 2020-03-31 | Cons. | Profit loss |
| Total assets | ¥123.0bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥121.6bn | at 2020-03-31 | Cons. | Assets |
| Total assets | ¥120.1bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥117.5bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥120.3bn | at 2017-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥43.7bn | at 2021-03-31 | Cons. | Liabilities |
| Total liabilities | ¥40.2bn | at 2020-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥79.3bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2020-03-31 | Cons. | Net assets |
| Net assets / equity | ¥80.3bn | at 2019-03-31d | Cons. | Net assets |
| Net assets / equity | ¥80.8bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥81.9bn | at 2017-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.1bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2020-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥11.2bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.1bn | at 2020-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.8bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥14.6bn | at 2017-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥7.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.5bn | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.9bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥8.4bn | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥487m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.8bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.7bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥68m | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥64m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-166.58 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.84 | 2019-04-01 → 2020-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.34 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.29 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.59 | 2016-04-01 → 2017-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,502.33 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,657.04 | at 2020-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,598.89 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,450.92 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,329.25 | at 2017-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 61.6% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2020-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.3% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.9% | at 2017-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -3.6% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2019-04-01 → 2020-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.6% | 2016-04-01 → 2017-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,009 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 2,003 | at 2020-03-31 | Cons. | Number of employees |
| Employees | 1,964 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 1,875 | at 2018-03-31d | Cons. | Number of employees |
| Employees | 1,870 | at 2017-03-31d | Cons. | Number of employees |
| Revenue | ¥34.4bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥37.0bn | 2019-04-01 → 2020-03-31 | Standalone | Net sales |
| Revenue | ¥40.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥38.8bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥36.4bn | 2016-04-01 → 2017-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥105m | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Operating income | ¥419m | 2019-04-01 → 2020-03-31 | Standalone | Operating income |
| Ordinary income | ¥943m | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2019-04-01 → 2020-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.0bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.8bn | 2016-04-01 → 2017-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥5.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.8bn | 2019-04-01 → 2020-03-31 | Standalone | Income before income taxes |
| Net income | −¥4.1bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2019-04-01 → 2020-03-31 | Standalone | Profit loss |
| Net income | ¥2.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.3bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.7bn | 2016-04-01 → 2017-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥88.8bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥88.7bn | at 2020-03-31 | Standalone | Assets |
| Total assets | ¥84.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥81.7bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥82.8bn | at 2017-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥37.2bn | at 2021-03-31 | Standalone | Liabilities |
| Total liabilities | ¥33.3bn | at 2020-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥51.6bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥55.5bn | at 2020-03-31 | Standalone | Net assets |
| Net assets / equity | ¥55.3bn | at 2019-03-31d | Standalone | Net assets |
| Net assets / equity | ¥57.6bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥58.0bn | at 2017-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2021-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2020-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-245.57 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.38 | 2019-04-01 → 2020-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.76 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.6 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.25 | 2016-04-01 → 2017-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2016-04-01 → 2017-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,064.29 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,297.38 | at 2020-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,293.74 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,287.96 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,168.42 | at 2017-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 58.1% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2020-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.1% | at 2017-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -7.7% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2019-04-01 → 2020-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.9% | 2016-04-01 → 2017-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,000,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2020-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,987,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,939,000 | at 2017-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 774 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 776 | at 2020-03-31 | Standalone | Number of employees |
| Employees | 768 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 739 | at 2018-03-31d | Standalone | Number of employees |
| Employees | 719 | at 2017-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥107m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥141m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥16.4bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥1.9bn |
| Chemicalreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥9.5bn |
| Chemicalreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥3.9bn |
| Chemicalreportable segment | employees | at 2021-03-31 | 1669 pure |
| Chemicalreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥78.1bn |
| Chemicalreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥76.8bn |
| Chemicalreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1.2bn |
| Chemicalreportable segment | segment assets | at 2021-03-31 | ¥93.1bn |
| Chemicalreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥5.7bn |
| Medicine And Healthcarereportable segment | capex | 2020-04-01 → 2021-03-31 | ¥982m |
| Medicine And Healthcarereportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥207m |
| Medicine And Healthcarereportable segment | employees | at 2021-03-31 | 271 pure |
| Medicine And Healthcarereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥8.3bn |
| Medicine And Healthcarereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥8.1bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥176m |
| Medicine And Healthcarereportable segment | segment assets | at 2021-03-31 | ¥13.6bn |
| Medicine And Healthcarereportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥452m |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥10.5bn |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥4.1bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥86.3bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥84.9bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| —segment total | segment assets | at 2021-03-31 | ¥106.6bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥6.2bn |
| Reconciling Itemsreconciling | capex | 2019-04-01 → 2020-03-31 | ¥80m |
| Reconciling Itemsreconciling | depreciation | 2019-04-01 → 2020-03-31 | ¥143m |
| Reconciling Itemsreconciling | revenue | 2019-04-01 → 2020-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2019-04-01 → 2020-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | segment assets | at 2020-03-31 | ¥11.9bn |
| Reconciling Itemsreconciling | segment profit | 2019-04-01 → 2020-03-31 | −¥2.2bn |
| Chemicalreportable segment | capex | 2019-04-01 → 2020-03-31 | ¥8.7bn |
| Chemicalreportable segment | depreciation | 2019-04-01 → 2020-03-31 | ¥3.3bn |
| Chemicalreportable segment | revenue | 2019-04-01 → 2020-03-31 | ¥79.9bn |
| Chemicalreportable segment | revenue external | 2019-04-01 → 2020-03-31 | ¥78.6bn |
| Chemicalreportable segment | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥1.4bn |
| Chemicalreportable segment | segment assets | at 2020-03-31 | ¥95.9bn |
| Chemicalreportable segment | segment profit | 2019-04-01 → 2020-03-31 | ¥5.6bn |
| Medicine And Healthcarereportable segment | capex | 2019-04-01 → 2020-03-31 | ¥320m |
| Medicine And Healthcarereportable segment | depreciation | 2019-04-01 → 2020-03-31 | ¥199m |
| Medicine And Healthcarereportable segment | revenue | 2019-04-01 → 2020-03-31 | ¥8.8bn |
| Medicine And Healthcarereportable segment | revenue external | 2019-04-01 → 2020-03-31 | ¥8.6bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥201m |
| Medicine And Healthcarereportable segment | segment assets | at 2020-03-31 | ¥13.9bn |
| Medicine And Healthcarereportable segment | segment profit | 2019-04-01 → 2020-03-31 | ¥594m |
| —segment total | capex | 2019-04-01 → 2020-03-31 | ¥9.1bn |
| —segment total | depreciation | 2019-04-01 → 2020-03-31 | ¥3.5bn |
| —segment total | revenue | 2019-04-01 → 2020-03-31 | ¥88.7bn |
| —segment total | revenue external | 2019-04-01 → 2020-03-31 | ¥87.2bn |
| —segment total | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥1.6bn |
| —segment total | segment assets | at 2020-03-31 | ¥109.7bn |
| —segment total | segment profit | 2019-04-01 → 2020-03-31 | ¥6.2bn |
| Chemicalreportable segment | employees | at 2021-03-31 | 705 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,779
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 57500 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 17000000 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 167795 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 163000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 163000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0096 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 163000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 163000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0096 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 252000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 15 | |
| Number of male directors and other officers | FilingDateInstant | 11 | |
| Number of female directors and other officers | FilingDateInstant | 1 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.0833 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000YabeMasaakiMember | 27597 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000YoshiokaAkiraMember | 13564 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000NakanishiAtsuyaMember | 9156 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000NakaharaShinjiMember | 3263 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000HattoriHiroyukiMember | 1782 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000YaguraToshiyukiMember | 3353 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000SasaiKazumiMember | 1596 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000ItoYoshikazuMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000WadaHiromiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000ZushiTadayukiMember | 1850 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000TakamatsuTeruyaMember | 216 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00780-000SadoMegumuMember | 8157 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 70534 | |
| Audit fees reporting company | Prior1YearDuration | 32000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 33000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | 28000000 | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | 28000000 | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | Prior1YearDuration | 61000000 | JPY |
| Non audit fees total | Prior1YearDuration | － | JPY |
| Audit fees total | CurrentYearDuration | 61000000 | JPY |
| Non audit fees total | CurrentYearDuration | － | JPY |
| Audit fees reporting company network firms | Prior1YearDuration | － | JPY |
| Non audit fees reporting company network firms | Prior1YearDuration | － | JPY |
| Audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Non audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries network firms | Prior1YearDuration | 1000000 | JPY |
| Non audit fees consolidated subsidiaries network firms | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries network firms | CurrentYearDuration | 1000000 | JPY |
| Non audit fees consolidated subsidiaries network firms | CurrentYearDuration | － | JPY |
| Audit fees total network firms | Prior1YearDuration | 1000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |